SCHEDULE: Tango Therapeutics: Ownership Update Filing

Tango Therapeutics, Inc. has filed an amendment to its Schedule 13G, detailing beneficial ownership as of June 30, 2026, with reporting persons holding 0.0% of the class.

Summary

• This filing is an amendment to Schedule 13G for Tango Therapeutics, Inc., reporting beneficial ownership as of June 30, 2026.
• The reporting persons include Nextech Crossover I SCSp, Nextech Crossover I GP S.a. r.l., Ian Charoub, Costas Constantinides, and Rocco Sgobbo.
• As of the reporting date, the aggregate amount of common stock beneficially owned by each reporting person is 0.00 shares.
• The percentage of the class represented by the amount beneficially owned is 0.0% for all reporting persons.
• The filing clarifies that Nextech Crossover GP is the general partner of Nextech Crossover LP, and Charoub, Constantinides, and Sgobbo are managers of Nextech Crossover GP, possessing power to direct voting and disposition of securities held by Nextech Crossover LP.
• The reporting persons expressly disclaim status as a 'group'.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership, with no new financial or strategic information.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for significant beneficial owners of public companies, indicating changes or confirmations of ownership stakes. This particular filing confirms a 0.0% ownership for the named entities, suggesting no significant stake as of the reporting date.

Stakeholder Impact

• Shareholders are informed of the beneficial ownership status of Nextech Crossover entities and individuals, confirming no significant stake as of the reporting date.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Tango Therapeutics, ownership update, Nextech Crossover